Previous close | 0.3350 |
Open | 0.3350 |
Bid | 0.3350 x 0 |
Ask | 0.3450 x 0 |
Day's range | 0.3350 - 0.3400 |
52-week range | 0.2300 - 0.4500 |
Volume | |
Avg. volume | 64,120 |
Market cap | 46.722M |
Beta (5Y monthly) | 0.30 |
PE ratio (TTM) | 11.33 |
EPS (TTM) | 0.0300 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 02 Sept 1999 |
1y target est | N/A |
Bioreactor Production of a Second Major Antigen – Increasing Capacity and FlexibilityMISSISSAUGA, Ontario, June 04, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has successfully adapted and extended the use of its bioreactor capabilities for production of another clinically and commercially-important test-ingredient (a native “Antigen”). This achievement will enhance production capa
Revenues of $5.6 million and Net Income of $0.4 millionMISSISSAUGA, Ontario, May 15, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2024 ended March 31, 2024 (“Q2” and “H1”), with strong growth in sequential and year-over-year quarterly revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients
With its stock down 12% over the past three months, it is easy to disregard Microbix Biosystems (TSE:MBX). However...